RxDoctor Payments Data

Gregory Cartnick, MD

Internal Medicine · Neptune, NJNPI 1710082094

Payments from drug & device makers

$812in general payments, 2019–2025

Across 26 payments — averaging $31.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$493
  • Exact Sciences$81
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$42
  • Sanofi Pasteur Inc.$34
  • Orexo US, Inc.$28
  • Almatica Pharma LLC$27
  • plus $107 from 7 others

What the payments were for

  • Food & beverage$812100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$812 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$20,185
Medicare patients
62
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol27$13,220
BrilintaTicagrelor16$9,885
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl76$9,431
Tresiba Flextouch U-200Insulin Degludec11$8,879
EliquisApixaban12$6,093
Combivent RespimatIpratropium/Albuterol Sulfate11$5,169
Arnuity ElliptaFluticasone Furoate23$5,054
Albuterol Sulfate HfaAlbuterol Sulfate106$3,444
Insulin Lispro Kwikpen U-100Insulin Lispro16$2,571
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,352
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen75$2,110
Ventolin HfaAlbuterol Sulfate27$1,713
Cyclobenzaprine Hcl42$1,214
Atorvastatin Calcium162$1,136
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$493$9,88516 claims
AbbVieSynthroid$12$56916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →